Redeye updates its estimates and valuation after OEM’s Q3 2025 report. Sales roughly aligned with what we pencilled in, while margins exceeded our projections. We judge that OEM’s combination of organic recovery and M&A optionality continues to present an attractive investment case for patient investors.
LÄS MER
